Last updated: October 15, 2026
The FDA approved ImmunityBio’s Anktiva with BCG for BCG unresponsive, high grade, papillary only bladder cancer on October 14 by extrapolating efficacy from carcinoma in situ data, nearly three months ahead of its January 6, 2027 decision date and without the randomized trial the agency once said was required.
This briefing covers the October 14, 2026 session: the Anktiva expansion, Medtronic’s final MiniMed exchange results, the first reaction sessions for Liquidia and Biomea, the Gilead and Vir engager deal, Zealand’s Generate collaboration, Freenome’s ACG presentation, and the day’s capital markets prints.
What did the FDA approve for ImmunityBio’s Anktiva?
The FDA approved Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG for adults with BCG unresponsive, high grade, papillary only non muscle invasive bladder cancer, per the agency’s October 14 announcement as reported by Fierce Pharma. It is the first FDA approved treatment specifically indicated for this papillary only population.
Anktiva, an IL-15 agonist, was first approved in 2024 for BCG unresponsive non muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The new approval extends it to patients whose disease is papillary only, a population the FDA itself had previously said would need a randomized trial. The decision arrived nearly three months before the January 6, 2027 target action date, extending the agency’s now well established pattern of acting ahead of PDUFA dates.
Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said in the agency’s release, as quoted by Fierce Pharma: “We listen to patients, clinicians and researchers, and we act when the science supports a new approach.”
How did the FDA approve a papillary only indication without a randomized trial?
The agency extrapolated. Rather than requiring new controlled data, the FDA concluded that “the prior demonstration of efficacy in patients with BCG-unresponsive NMIBC containing CIS could be extrapolated” to papillary only disease, per its announcement as reported by Fierce Pharma, reasoning that both are aggressive urothelial carcinomas.
The evidence base is the Quilt-3.032 study. Cohort A, the 77 patient carcinoma in situ cohort that supported the 2024 approval, showed a 62% complete response rate, with 48% of complete responders maintaining response at least 12 months and a 40% duration of response rate at 24 months. Cohort B, the 80 patient papillary only cohort, met its primary endpoint with a 12 month disease free survival rate of 58.2%, a figure reported in the American Urological Association’s journal and cited by ImmunityBio; per Fierce Pharma, the FDA’s October 14 announcements did not reference Cohort B. The agency also said it is finalizing draft guidance on drug development for BCG unresponsive non muscle invasive bladder cancer, including the use of carcinoma in situ evidence to support papillary only approvals. All figures here are attributed to those reports; we have not yet retrieved the FDA notice page directly.
Why is the Anktiva decision a reversal for the FDA?
Seventeen months ago the agency refused to even file this application. In May 2025 the FDA issued a refusal to file letter for the papillary expansion. The approval that arrived Wednesday rests on the same single arm cohort the agency once deemed insufficient, now buttressed by extrapolation logic.
| Date | Event |
|---|---|
| April 2024 | Anktiva approved for BCG unresponsive NMIBC with carcinoma in situ, with or without papillary tumors |
| May 2025 | FDA issues refusal to file letter for the papillary only supplement; ImmunityBio says the agency had “unambiguously invited” the submission |
| January 2026 | STAT reports, citing people familiar with the FDA’s side, that the agency never endorsed the plan and flagged the lack of a randomized control group |
| Early 2026 | Chairperson Patrick Soon-Shiong says he met with White House and HHS officials, including Robert F. Kennedy Jr. and then Commissioner Marty Makary |
| March 2026 | ImmunityBio refiles; FDA accepts in May 2026 with a January 6, 2027 action date |
| May 2026 | FDA workshop discusses similarity between carcinoma in situ and papillary disease |
| October 14, 2026 | FDA approves the papillary only indication by extrapolation, nearly three months early |
The timeline, drawn from Fierce Pharma’s reporting, matters beyond one company. A sponsor that was refused at the door in 2025 reached an approval in 2026 on the same core dataset after the agency changed how it weighs evidence across histologies.
What does the papillary approval mean for Johnson & Johnson’s Inlexzo?
J&J is running Sunrise-5, the randomized Phase 3 trial in papillary disease it launched in April 2024, and the FDA just approved a competitor in that population without one. Fierce Pharma’s read is that the agency’s new stance suggests the trial may now be unnecessary as a regulatory requirement.
The commercial stakes are current. On its Tuesday third quarter update, J&J put Inlexzo sales at roughly $200 million year to date, including north of $90 million in the third quarter, with nearly one in three eligible new patient starts, per the company’s remarks as reported by Fierce Pharma. ImmunityBio reported $95 million in product revenue for the first half of 2026, per its second quarter release. The papillary population J&J sized for Sunrise-5 is roughly 15,000 patients, against about 4,000 for the carcinoma in situ indication, per J&J executive comments quoted by Fierce. The market’s first grade of the new approval was mild: IBRX closed at $9.91, up 1.1% on the session, our arithmetic on exchange settled closes.
What were the final results of Medtronic’s MiniMed exchange offer?
Medtronic accepted 55,032,401 of its ordinary shares at a final proration factor of 18.289133% and will exchange its entire remaining stake of 252,813,348 MiniMed shares, retaining none, per the company’s October 14 release.
The final count, from the Medtronic release: 297,521,390 Medtronic shares were validly tendered, of which 296,763,500 were subject to proration and 757,890 were odd lot shares exempt from proration and accepted in full. The final factor confirms the preliminary ~18.3% reported last week. Tendered shares not accepted are being returned promptly in book entry form, and the exchange agent will credit new MiniMed shares promptly, with fractional shares aggregated, sold, and paid in cash. The release gives no specific settlement dates.
| MiniMed exchange offer, final results (per Medtronic, Oct 14) | Figure |
|---|---|
| Medtronic shares validly tendered | 297,521,390 |
| Shares subject to proration | 296,763,500 |
| Odd lot shares (exempt, accepted in full) | 757,890 |
| Final proration factor | 18.289133% |
| Medtronic shares accepted | 55,032,401 |
| MiniMed shares Medtronic exchanges | 252,813,348 (entire remaining interest) |
Where is MiniMed stock trading as the distribution approaches?
MMED settled at $16.81 on Wednesday, down 8.6% on the session and down from $19.30 on October 7, our arithmetic on exchange data. That tape remains a pre distribution market; the shares backing the exchange have not yet been credited to tendering holders.
At the 4.5939 exchange ratio, Wednesday’s MMED close implies about $77.23 of MiniMed stock per accepted Medtronic share, our arithmetic, against Medtronic’s $94.23 close, up 1.3% on the day. That gap has widened from roughly 9% a week ago to roughly 18% now, our arithmetic throughout, versus the 7% discount the exchange formula was designed to deliver. The direction of travel is the point: as the distribution nears and the arbitrage demand that supported the when issued style tape unwinds, MiniMed’s price is sliding toward whatever a real float will pay. The first sessions after the shares actually land remain the clean read, and we will grade them when they arrive.
How did the market grade the Liquidia settlement and Biomea’s oral GLP-1 data?
Wednesday was the first session in which either could trade on the news, and the market graded them in opposite directions: Liquidia rose 26.6% and Biomea fell 33.8%, our arithmetic on exchange settled closes.
Liquidia closed at $33.94, up from $26.81, after Tuesday evening’s global settlement with United Therapeutics: $380.7 million in net payments, six matters dismissed with prejudice, Yutrepia continuing in PAH while the PH-ILD indication comes off the label. United Therapeutics slipped 0.6% to $540.03. The market read $380.7 million as cheap for certainty; a quarter of Liquidia’s equity value appeared on the removal of litigation risk, not on any new revenue.
Biomea closed at $0.834, down from $1.26, in its first session after releasing Phase 1 data for BMF-650, its oral GLP-1 receptor agonist, and announcing it would seek a partner for late stage development. The release’s own caveat, that the striking 6.1% weight loss in the confined Cohort 5 came alongside placebo patients who ate about a third of provided calories and lost similar weight, was evidently the market’s read too. A dosed oral GLP-1 asset pitched for partnership lost a third of its value in a day, which says as much about the oral GLP-1 shelf as about Biomea.
What did Gilead agree to pay Vir for masked T cell engagers?
Gilead licensed three PRO-XTEN dual masked T cell engager development candidates against selected solid tumor antigens for $90 million upfront, comprising $65 million in cash and a $25 million equity investment at a 30% premium, plus up to $45 million in near term preclinical milestones and up to $1.74 billion in further milestones, per Vir’s 8-K press release exhibit.
Vir discovers, designs, and optimizes the candidates; Gilead holds the exclusive license to develop and commercialize them, with tiered high single digit to low double digit royalties on net sales. The combined milestone total works out to $1.875 billion, our arithmetic on the release components; trade headlines rounding to $1.9 billion are describing the same structure. This is Vir’s second collaboration built on the PRO-XTEN masking technology, which it licenses exclusively for oncology and infectious disease; the mask is designed to keep the engager inert until tumor proteases cut it loose. Vir CEO Marianne De Backer told Fierce Biotech the three targets were ones Vir “were not interested in exploring ourselves” and said more masked engager deals are possible. VIR closed at $10.41, down 1.9% on the day, our arithmetic: the market paid nothing for a deal that hands three preclinical programs to a buyer at biobucks ratios of roughly twenty to one against the cash upfront.
Why did Zealand Pharma partner with Generate Biomedicines?
Zealand is buying protein engineering capacity it does not have. The companies agreed to develop multispecific protein therapeutics for metabolic disease, starting with two programs, for $30 million upfront and up to $35 million in early preclinical milestones, per the announcement as reported by Fierce Biotech.
Generate’s AI enabled protein design platform runs the programs through lead candidate selection, then Zealand takes clinical development. Total potential payments were characterized as nearly $1.2 billion by Fierce Biotech and up to $1.3 billion by Endpoints News; we print the verified components and attribute the totals, since the primary release was not retrieved. The strategic read is the familiar one from this week: Zealand’s lead obesity assets, petrelintide with Roche and survodutide with Boehringer Ingelheim, are peptides, and the company is paying seed scale money to add a modality. Together with Roche’s $100 million upfront for Rona’s preclinical ALK7 RNAi candidate a day earlier and Gilead’s $65 million cash for three preclinical engagers, the pattern is pharma and large biotech paying single digit to low double digit millions up front for engineering platforms while clinical stage assets without partners, like Biomea’s, struggle to clear at any price.
What did Freenome present at ACG 2026, and what was actually new?
The podium confirmed the figures Freenome had already published and added subtype claims without numbers. Aasma Shaukat of NYU presented the updated SimpleScreen CRC validation data in a late breaking oral at ACG in Nashville on Wednesday, matching the company’s July topline and its October 11 announcement.
| Measure | First generation (PREEMPT CRC) | Updated test (validation study) |
|---|---|---|
| Advanced precancerous lesion sensitivity | 13.7% | 18.2% |
| APL with high grade dysplasia sensitivity | 30.5% | 41.9% |
| Colorectal cancer sensitivity | reported as consistent across versions | 80.4% |
| Specificity (no findings on colonoscopy) | — | 90% |
All figures per Freenome’s October 11 release as carried by RTT News and Patient Care Online; results were adjusted to the age and sex distribution of the US Census. What the presentation added versus July was directional: improved sensitivity across advanced precancerous lesion subtypes including villous or tubulovillous adenomas, adenomas of at least 10 mm, sessile serrated lesions of at least 10 mm, and traditional serrated adenomas, with no figures disclosed for any subtype. The company’s claim that these are the highest such sensitivities for a blood based test in a prospective registrational pivotal study is a company claim. We found no new Freenome release on October 14 itself as of Wednesday night, and the tape kept selling: FRNM closed at $12.19, down 3.6%, our arithmetic, a third straight decline that has now run through the presentation the stock was presumably waiting for. The supplemental PMA and the $70 million Abbott milestone remain the thread to watch.
What happened in life sciences capital markets on October 14?
Iambic priced its IPO at face value, Ultragenyx sold its second voucher in a week, and the Retension closing release stayed absent. The window remains open and unpaid for.
Iambic, the NVIDIA backed AI drug discovery company, priced 9,375,000 shares at $16.00 for $150.0 million gross, inside its $15 to $17 range, with a 30 day option on 1,406,250 additional shares, per the pricing release. Shares begin trading Thursday on Nasdaq as IAM, with closing expected October 16. Lead program IAM1363 is an oral brain penetrant HER2 inhibitor in Phase 1. Another deal clearing at face value extends the standing read on this window: deals get done, nobody pays a premium, and the aftermarket decides later. TRexBio, which closed its $116.7 million IPO Tuesday, settled at $13.50 Wednesday, below its first day close.
Ultragenyx, meanwhile, announced the sale of a second rare pediatric disease priority review voucher for $203 million, the one earned with September’s Fayuvi approval, a week after selling its Genglycos voucher for $210 million, per the company’s announcements as reported by Fierce Pharma. Neither buyer was named. The pair totals $413 million against 2026 comps of $200 million for Jazz, $205 million for Fortress, and $180 million for Rocket, per Fierce. Two gene therapy approvals have now been converted into non dilutive capital worth more than many biotech IPOs this cycle, at prices holding firm near the top of the year’s range.
Which stocks moved on October 14, 2026, and why?
Moves that carry a story, settled closes, percentages our arithmetic. Biotech held flat on a down tape: XBI closed at $146.77, essentially unchanged, while the SPY fell 1.1%.
| Ticker | Close | Move | The story |
|---|---|---|---|
| LQDA | $33.94 | +26.6% | First reaction to the United Therapeutics global settlement; the market paid a certainty premium of a quarter of the company |
| BMEA | $0.834 | −33.8% | First reaction to BMF-650 Phase 1 data and the partner search; the confinement caveat was the market’s read too |
| MMED | $16.81 | −8.6% | Final proration at 18.289133%; the pre distribution tape slides toward real float pricing |
| FRNM | $12.19 | −3.6% | Third straight decline; the ACG podium added subtype claims, not figures |
| JNJ | $253.91 | +2.1% | Day after clearing 5.7% lower on a beat and raise; roughly a third of the drop retraced |
Frequently asked questions
What is Anktiva and how does it work?
Anktiva (nogapendekin alfa inbakicept-pmln) is ImmunityBio’s IL-15 agonist, given with BCG into the bladder. It stimulates natural killer cells and T cells to attack bladder tumors, and it was first approved in April 2024 for BCG unresponsive non muscle invasive bladder cancer with carcinoma in situ.
What new indication did Anktiva receive on October 14, 2026?
The FDA approved Anktiva with BCG for adults with BCG unresponsive, high grade, papillary only non muscle invasive bladder cancer, per the agency’s announcement as reported by Fierce Pharma. It is the first FDA approved therapy specifically for this papillary only population.
Why is the Anktiva papillary approval controversial?
The FDA refused to file the same expansion in May 2025, citing, per later reporting, the lack of a randomized control group. The agency then approved it in October 2026 by extrapolating efficacy from carcinoma in situ patients, without new randomized data, while J&J continues to run a randomized Phase 3 in the same population.
Does the Anktiva decision affect Johnson & Johnson’s Sunrise-5 trial?
Possibly. Fierce Pharma’s reporting suggests the FDA’s willingness to extrapolate across histologies may make a randomized papillary trial unnecessary as a regulatory requirement. J&J’s Inlexzo has roughly $200 million in sales year to date per company remarks, so the commercial contest proceeds regardless.
What was the final proration factor in Medtronic’s MiniMed exchange offer?
18.289133%, per Medtronic’s October 14 release. Of 297,521,390 shares tendered, Medtronic accepted 55,032,401, with 757,890 odd lot shares exempt from proration and accepted in full. Medtronic is exchanging its entire remaining 252,813,348 MiniMed shares and will retain none.
When do investors receive their MiniMed shares?
Promptly, per the release, which gives no specific dates. The exchange agent credits new MiniMed shares in book entry form through the transfer agent, returns unaccepted Medtronic shares, and pays cash in lieu of fractional shares after selling them in the open market.
Why did Liquidia stock jump 26.6% on October 14?
It was the first session after Tuesday evening’s global settlement with United Therapeutics: $380.7 million in net payments, six matters dismissed with prejudice, Yutrepia continuing in PAH without disruption while Liquidia removes PH-ILD from the label. The market paid for the end of litigation risk.
Why did Biomea Fusion stock fall 33.8%?
It was the first session after Biomea released Phase 1 BMF-650 oral GLP-1 data and said it would seek a partner for late stage development. The strongest weight loss came from a confined cohort the company itself said should be read separately, and the market discounted accordingly.
What are the terms of the Gilead and Vir T cell engager deal?
Per Vir’s 8-K: $90 million upfront ($65 million cash plus a $25 million equity investment at a 30% premium), up to $45 million in near term preclinical milestones, up to $1.74 billion in further milestones, and tiered high single digit to low double digit royalties, for three PRO-XTEN dual masked T cell engagers against solid tumor antigens.
What is PRO-XTEN masking technology?
A universal masking approach, originally from Amunix, now a Sanofi company, that keeps a T cell engager inactive in circulation until tumor associated proteases remove the mask, concentrating activity in the tumor. Vir holds exclusive rights in oncology and infectious disease and has now built two collaborations on it.
What did Zealand Pharma agree to pay Generate Biomedicines?
$30 million upfront plus up to $35 million in early preclinical milestones for two initial multispecific protein programs in metabolic disease, with total potential payments that Fierce Biotech put at nearly $1.2 billion and Endpoints News at up to $1.3 billion, per the companies’ announcement as reported by those outlets.
What did Freenome’s updated SimpleScreen CRC test show at ACG 2026?
Colorectal cancer sensitivity of 80.4%, advanced precancerous lesion sensitivity of 18.2% versus 13.7% for the first generation test, high grade dysplasia lesion sensitivity of 41.9% versus 30.5%, and 90% specificity, per the company’s release. The presentation added subtype improvement claims without disclosing subtype figures.
What price did Iambic’s IPO achieve?
$16.00 per share for 9,375,000 shares, $150.0 million gross, inside the $15 to $17 marketed range, per the pricing release. Trading begins Thursday, October 15 on Nasdaq under IAM, and the deal is expected to close October 16.
How much has Ultragenyx raised from priority review voucher sales in October 2026?
$413 million across two sales, per the company’s announcements as reported by Fierce Pharma: $210 million for the voucher earned with Genglycos, announced October 7, and $203 million for the Fayuvi voucher, announced October 14. Neither buyer was named.
Sources
Primary sources (October 13 to 14, 2026): Medtronic news release, “Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer” (October 14); Vir Biotechnology Form 8-K press release exhibit on the Gilead collaboration (SEC, October 14); Iambic IPO pricing release (Business Wire, October 14); Agilent news release on the Proscia acquisition (October 13); Liquidia Corporation settlement release (October 13, investors.liquidia.com); Biomea Fusion BMF-650 results release (GlobeNewswire, October 13); Medtronic SC TO-I/A Amendment No. 3 (SEC, October 13).
Trade and press coverage (October 14, 2026): Fierce Pharma on the Anktiva approval, quoting the FDA press release and FDA announcement, and on the Ultragenyx voucher sales and Galderma’s Zo Skin Health acquisition; Fierce Biotech on the Gilead and Vir deal, the Zealand and Generate collaboration, Verdiva’s trial termination, and GSK’s Belgium restructuring; Endpoints News headlines on the Zealand deal and Arrowhead’s ARO-MAPT webinar; MedTech Dive on the Agilent and Proscia deal; RTT News and Patient Care Online carrying Freenome’s October 11 release; StockTitan carries of the Takeda Orzeyful launch and Dexcom CONNECT publication releases.
Market data: Exchange settled closing prices via Robinhood (sip list exchange close), October 14, 2026; percentage moves are our arithmetic against October 13 settled closes.
Related coverage
For the J&J third quarter clearing price and the Liquidia settlement terms, read our October 14 briefing: J&J raised guidance on 5.9% growth and fell 5.7% as Liquidia paid $380.7 million for peace with United Therapeutics and Syndax exited IPF.
For the First Tracks celiac data and the Medtronic MiniMed preliminary proration, read our October 13 briefing: First Tracks’ ANB033 prevented gluten damage in celiac disease as Mirum’s Livmarli hit in Phase 3 EXPAND and Bristol Myers claimed two pivotal wins.
For the FDA’s Friday approval set and the Merck retina data, read our October 12 briefing: Merck’s remigromig gained 9.1 letters to ranibizumab’s 11.8 in pivotal diabetic macular edema data as the FDA stacked three approvals into one Friday.
